文献类型：期刊文献

英文题名：Structural characterization and antiviral activity of two fucoidans from the brown algae Sargassum henslowianum

作者：Sun, Qi-Li[1,4];Li, Yi[2,3];Ni, Long-Quan[2,3];Li, Yi-Xuan[1,4];Cui, Yong-Sheng[1];Jiang, Si-Liang[1,4];Xie, En-Yi[5];Du, Juan[4];Deng, Fei[2,3];Dong, Cai-Xia[1]

机构：[1]Tianjin Med Univ, Sch Pharm, Tianjin Key Lab Technol Enabling Dev Clin Therape, Tianjin 300070, Peoples R China;[2]Chinese Acad Sci, Wuhan Inst Virol, State Kay Lab Virol, Wuhan 430071, Hubei, Peoples R China;[3]Chinese Acad Sci, Wuhan Inst Virol, Natl Virus Resource Ctr, Wuhan 430071, Hubei, Peoples R China;[4]Jiamusi Univ, Coll Pharm, Dept Pharmacognosy, Jiamusi 154007, Peoples R China;[5]Guangdong Ocean Univ, Coll Fisheries, Zhanjiang 524088, Peoples R China

年份：2020

卷号：229

外文期刊名：CARBOHYDRATE POLYMERS

收录：SCI-EXPANDED(收录号：WOS:000501796600119)、、EI(收录号：20194507633742)、Scopus(收录号：2-s2.0-85074416811)、WOS

基金：This work was supported by the National Natural Science Foundation of China [81803682] and partially sponsored by the project from Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnosis [CTD2018-03].

语种：英文

外文关键词：Brown algae; Sargassum henslowianum; Fucoidans; Antiviral; Herpes simplex virus

外文摘要：Purified fucoidans SHAP-1 and SHAP-2 with apparent molecular weights of 6.55 x 10(5) and 5.89 x 10(5), respectively, were isolated from Sargassum henslowianum by ion-exchange and gel-filtration column chromatography. They are both composed of fucose and galactose at a ratio of around 3:1 and 31.9% sulfate. The backbone of two fucoidans consists of alpha-(1 -> 3)-linked L-Fucp residues which are mainly sulfated on the C-2 and C-4 positions. Side chains composed of terminally linked alpha-L-Fucp and alpha-D-Galp residues, and (1 -> 2)-, (1 -> 6)-, and (1 -> 2,6)-linked beta--Galp residues attach mainly at O-4 position of backbone residues. Antiviral test showed that the IC50 values of SHAP-1 and SHAP-2 against HSV-1 were estimated to be 0.89 and 0.82 mu g/mL by plaque reduction assay, respectively, whereas both as low as 0.48 mu g/mL against HSV-2. The antiviral mechanism of the fucoidans might be at least through blocking HSV-2 virion adsorption to host cells. These results suggest that the fucoidans have potential clinical applications.